SAN DIEGO, June 15, 2015 /PRNewswire/ -- OncoSec
Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced it
is set to join the Russell Microcap Index at the conclusion of
the Russell indexes annual reconstitution on June 26, according to a preliminary list of
additions posted on June 12.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
"We are pleased to be added to the Russell Microcap Index
to raise OncoSec's visibility and public awareness within the
investment community," said Punit
Dhillon, President and CEO of OncoSec. "As we continue to
execute on our growth strategy, we believe our inclusion in this
index will serve as a valuable tool to help broaden our shareholder
base and further advance our intratumoral immunotherapy
products."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the
Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell 1000 and the Russell indexes
reconstitution, please visit the "Recon Central" section on the
FTSE Russell website.
About FTSE Russell
FTSE Russell is a global index
leader that provides innovative benchmarking, analytics and data
solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 80 countries, covering 98% of the investable
market globally and trading on over 25 exchanges worldwide. FTSE
Russell index expertise and products are used extensively by
institutional and retail investors globally. Leading asset owners,
asset managers, ETF providers and investment banks use FTSE Russell
indexes to benchmark their investment performance and create ETFs,
structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance. FTSE Russell is also focused on
index innovation and client collaboration as it seeks to enhance
the breadth, depth and reach of its offering. FTSE Russell is
wholly owned by London Stock Exchange Group. For more information,
please visit www.ftserussell.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its investigational
ImmunoPulseTM intratumoral cancer immunotherapy. OncoSec
Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulseTM have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response limiting the systemic
toxicities associated with other treatments. OncoSec's lead program
evaluating ImmunoPulseTM for the treatment of metastatic
melanoma is currently in Phase II development, and is being
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate
ImmunoPulseTM in its current indications, it is also
focused on identifying and developing new immune-targeting agents,
investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medical-set-to-join-russell-microcap-index-300098846.html
SOURCE OncoSec Medical Inc.